Overall allelic association with cancer was significant for rs822396 (odds ratio (OR) = 0.91; P = 0.045) and rs1501299 (OR = 0.89; P = 0.051), with low or moderate heterogeneity.
In this study, with a total of 19 eligible articles consisting of 52 studies, the pooled odds ratios (ORs) for the association between ADIPOQ rs1501299 and cancer risk were statistically significant (dominant model, TT/GT vs. GG, OR=0.84, 95% confidence interval [CI]: 0.77-0.92; homozygous model, TT vs. GG, OR=0.80, 95% CI: 0.68-0.94).
Similarly, combined analysis also indicated that adiponectin rs1501299G/T polymorphism was not associated with risk of cancer development (OR (95 % CI) 0.86 (0.73-1.01) for TT vs. GG, P z test = 0.07 and 1.17 (0.98-1.39), P z test = 0.08).